Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast Cancer

Mohammad Jahanzeb, MD
Published: Wednesday, Mar 21, 2018



Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Jahanzeb says that the most significant advancements made in the treatment of patients with HER2-positive breast cancer in the last few years have been in the adjuvant setting. The NSABP B-47 trial, which aimed to determine the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in patients with low levels of HER2 protein, showed that there was no significant added efficacy.

Jahanzeb said that although this trial was negative, the fact that a large trial such as this occurred is important. It also provided the community with a definitive answer.


Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Jahanzeb says that the most significant advancements made in the treatment of patients with HER2-positive breast cancer in the last few years have been in the adjuvant setting. The NSABP B-47 trial, which aimed to determine the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in patients with low levels of HER2 protein, showed that there was no significant added efficacy.

Jahanzeb said that although this trial was negative, the fact that a large trial such as this occurred is important. It also provided the community with a definitive answer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x